Softgel H2 Antagonist Suspension for Stable Fast-Release Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Histamine H2-receptor antagonists like famotidine are difficult to formulate in liquid media due to poor lipophilicity, poor aqueous solubility, and low stability outside a pH range of 6 to 7, leading to challenges in taste masking, stability, and ease of swallowing in oral dosage forms.
Innovation Solution
A soft gelatin capsule containing a suspension of H2 receptor antagonists, such as famotidine, in a hydrophobic/lipophilic excipient like glyceryl monolinoleate or corn oil, substantially free from water, which maintains stability and ease of swallowing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If H2 receptor antagonists are formulated in liquid media, then dissolution and release are improved, but stability deteriorates due to poor lipophilicity and low stability outside pH range 6-7
Solution Approach 1:
The patent changes the pH parameter of the liquid medium by incorporating pH buffering agents (such as sodium citrate, citric acid, or phosphoric acid) to maintain the pH within the stable range of 6-7. This allows the H2 receptor antagonist to remain stable in liquid formulation while still achieving rapid dissolution and release.
Solution Approach 2:
The patent uses composite liquid formulations combining multiple components including pH buffering agents, surfactants (such as polysorbate 80 or lecithin), and co-solvents (such as glycerin or propylene glycol). This composite approach addresses both stability and dissolution requirements by creating a synergistic liquid medium that maintains drug stability while enhancing solubility and release.
2Productivity
If H2 receptor antagonists are incorporated into chewable or fast dissolving tablets, then dissolution is improved, but taste masking becomes necessary due to bitter taste
Solution Approach 1:
The patent employs taste-masking intermediaries such as flavored coatings, encapsulation materials, or taste-modifying agents that interact with the bitter H2 receptor antagonist. These intermediaries form a barrier or modify the perception of bitterness, allowing the medication to be administered in pleasant-tasting liquid or chewable forms without compromising the active ingredient's efficacy.
Solution Approach 2:
The patent applies local quality modification by creating zones of different properties within the dosage form. For example, the H2 receptor antagonist is localized in microcapsules or specific formulation zones that are coated or surrounded by taste-masking materials, so that the bitter taste is confined to specific areas that do not contact the patient's taste buds directly.
3Ease of manufacture
If hard tablets or hard-shell capsules are used, then manufacturing is simplified, but ease of swallowing deteriorates for consumers with difficulty swallowing
Solution Approach 1:
The patent transitions from static hard dosage forms to dynamic liquid-filled softgel capsules. The liquid fill allows the capsule to be more flexible and pliable, making it easier to swallow. The liquid formulation also enables the capsule to adapt its shape slightly during swallowing, reducing resistance and improving patient compliance for those with dysphagia.
Solution Approach 2:
The patent employs flexible softgel capsules made from gelatin or hydroxypropyl methylcellulose shells that are more pliable than hard capsules. These flexible shells can deform during swallowing and are easier to ingest, while still providing adequate protection for the liquid pharmaceutical composition inside.
4Ease of operation
If liquid filled gelatin capsules are used, then ease of swallowing and release speed are improved, but formulation difficulty increases due to poor lipophilicity and aqueous solubility
Solution Approach 1:
The patent introduces surfactants and co-solvents as intermediary substances that mediate between the hydrophobic H2 receptor antagonist and the aqueous environment. These intermediaries reduce surface tension, enhance wetting, and improve solubility, making the liquid formulation process more manageable despite the drug's poor lipophilicity and aqueous solubility characteristics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation ensures stability of H2 receptor antagonists for up to 2 years, maintains a high content of the active ingredient, and provides faster action on symptom relief, making it easier to swallow and more appealing to users.
Implementation Method 1
the liquid fill is a suspension of an H2 receptor antagonist in a hydrophobic/lipophilic excipient substantially free from water
Implementation Method 2
Liquid filled gelatin capsules may also provide a faster release of the active ingredient present in the liquid fill once the gelatin capsule is dissolved in the stomach
Data Source
AI summary
The disclosure generally relates to soft gelatin oral dosage form. In particular the disclosure relates to an oral dosage form comprising a soft gelatin capsule and a liquid fill, where the liquid fill is a suspension of an H2 receptor antagonist in a hydrophobic/lipophilic excipient. The disclosure also relates to a method of treating a gastric disease or disorder by using said oral dosage form.